Inhibikase reports Q2 2026 results as Phase 3 PAH trial expands across 26 countriesAug 11Quarterly updateInhibikase Therapeutics
FDA grants orphan drug status to Inhibikase's IKT-001 for PAHJul 23Regulatory milestoneIKT-001Inhibikase Therapeutics
Sign inSign in